Deutsche Bank Slashes Intuitive Surgical (ISRG) To Sell from Neutral

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best stocks to buy. On June 9, Deutsche Bank slashed its rating for ISRG from Neutral to Sell, trimming the price target from $440 to $515. Deutsche Bank announced that it will hold an investor webinar with Jon Reuter, COO of Keck Hospitals of USC, on June 9, to explore how hospitals are viewing Intuitive’s remanufactured Endowrist instruments. The bank projected rising competition for Intuitive Surgical, signaling potential headwinds ahead.

Deutsche Bank, though confident in da Vinci’s lasting dominance, pointed to several upcoming rival systems, including Medtronic’s Hugo, expected FDA approval in late 2025, as potential threats to ISRG’s competitive edge.

Even with a Sell rating, the firm highlighted the da Vinci system as a historic disruptor within medical technology.

A medical team performing minimally invasive surgery with a da Vinci Surgical System.

Deutsche Bank noted that shareholders have realized substantial gains, with shares soaring more than 26,000% since the company’s IPO in 2000, compared to a nearly 500% rise in the broader market, and ISRG remains a bullish idea.

Intuitive Surgical, Inc. (NASDAQ:ISRG) develops robotic systems like da Vinci and Ion to advance minimally invasive procedures, supported by specialized tools, training, and digital services to enhance surgical outcomes and healthcare efficiency.

While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.